QuVa Pharma has announced expansion plans of its biotech pharmaceutical manufacturing facility in Bloomsbury, New Jersey.
This expansion will increase QuVa Pharma's production and distribution capabilities at the New Jersey site.
QuVa Pharma's existing manufacturing plant in Bloomsbury is an FDA 503B registered facility covering an area of 160,000 square-foot, featuring two interconnected buildings, with future expansion into a state-of-the-art 240,000 square feet facility by improving the cleanroom.
The facility expansion will be cGMP compliant and added with operation capacity for running a second shift.
Moreover, the facility will help to serve customers with a wide range of ready-to-use compounded sterile medications sourced from various starting materials such as FDA-approved pharmaceutical formulations and active pharmaceutical ingredients and will also supply medicine during a drug shortage.
The current phase of the expansion will be completed by the fourth quarter of 2019, while the entire expansion project is expected to be completed by 2020.